Itraconazole Injection

Abstract

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 1999 Formulary monographs are on adefovir dipivoxil, meloxicam, reboxetine mesylate, ketotifen fumarate ophthalmic solution, and rapacuronium. The DUE is on pioglitazone.

Get full access to this article

View all access options for this article.

References

Sporanox Injection package literature. Janssen Pharmaceutical; March 1999.

Van Cutsem

Oral and parenteral treatment with itraconazole in various superficial and systemic experimental fungal infections. Comparisons with other antifungals and combination therapy. Br J Clin Pharmacol. 1990; 71(suppl): 32–40.

Van Cutsem

Oral, topical and parenteral antifungal treatment with itraconazole in normal and in immunocompromised animals. Mycoses. 1989; 32(suppl 1): 14–34.

Miyazaki

H.M.

Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis. Antimicrob Agents Chemother. 1993; 37: 2762–5.

Van Cutsem

Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: Animal models. Rev Infect Dis. 1987; 9(suppl 1): S15–32.

Vandewoude

Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother. 1997; 41: 2714–8.

Prentice

H.G.

Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: Meeting report. Acta Haematol. 1999; 101: 56–62.

Zhou

A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol. 1998; 38: 593–602.

Heykants

The clinical pharma-cokinetics of itraconazole: An overview. Mycoses. 1989; 32(suppl 1): 67–87.

10.

Poirier

J-M

, Cheymol

Optimisation of itraconazole therapy using target drug concentrations. Drugs. 1998; 35: 461–73.

11.

De Beule

The pharmacokinetic rationale behind intravenous itraconazole [abstract]. 35th Interscience Conference on Antimicrobial Agents. San Francisco, CA; 1720 September 1995, A67.

12.

Boogaerts

Pharmacokinetics and safety of seven days intravenous (I.V.) itraconazole (ITR) followed by two weeks oral ITR solution in patients with haematologic malignancy [abstract]. 36th Interscience Conference on Antimicrobial Agents. New Orleans, LA; 15-18 September 1996, A087.

13.

Zhou

Pharmacokinetic study of itraconazole in patients with advanced HIV infection [abstract]. 36th Interscience Conference on Antimicrobial Agents. New Orleans, LA; 15-18 September 1996, A054.